home / stock / arfxf / arfxf news

ARFXF News and Press, Amorfix Life Sciences Ltd From 10/07/21

Stock Information
Company Name: Amorfix Life Sciences Ltd
Stock Symbol: ARFXF
Market: OTC
Website: promisneurosciences.com
Menu
ARFXF ARFXF Quote ARFXF Short ARFXF News ARFXF Articles ARFXF Message Board
Get ARFXF Alerts

News, Short Squeeze, Breakout and More Instantly...
ARFXF - ProMIS Neurosciences Announces Special Shareholder Meeting

TORONTO and CAMBRIDGE, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (the “ Company ”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the deve...
ARFXF - ProMIS Neurosciences to Present at the Second Annual Undruggable Leaders Forum, September 15-16, 2021

TORONTO and CAMBRIDGE, Mass., Sept. 15, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative disea...

ARFXF - ProMIS Neurosciences to Participate in H.C. Wainwright & Co. 23rd Annual Investment Conference

TORONTO and CAMBRIDGE, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative disea...

ARFXF - ProMIS Neurosciences appoints accomplished biotechnology executive, Josh Mandel-Brehm, to its Board of Directors

TORONTO and CAMBRIDGE, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegen...
ARFXF - ProMIS Neurosciences Closes Upsized US$20,125,000 Public Offering

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO and CAMBRIDGE, Mass., Aug. 25, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (the “ Company ” or “ ProMIS ”), a biotechnology company ...

ARFXF - ProMIS Neurosciences Inc. Announces Upsize of Previously Announced Public Offering of Units to US$17.5M

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Aug. 18, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc.  (“ ProMIS ” or the “ Company ”) (TSX: PMN), a biotechnology company focused on the di...

ARFXF - ProMIS Neurosciences Inc. Announces Pricing of US$15 Million Public Offering of Units

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Aug. 18, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc.  (“ ProMIS ” or the “ Company ”) (TSX: PMN), a biotechnology company focused on the disc...
ARFXF - ProMIS Neurosciences Inc. Announces US$15 Million Offering of Units

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Aug. 17, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (“ ProMIS ” or the “ Company ”) (TSX: PMN), a biotechnology company focused on the discover...

ARFXF - ProMIS Neurosciences Announces Second Quarter 2021 Results

TORONTO and CAMBRIDGE, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS or the Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the...

ARFXF - ProMIS Neurosciences Issues Chairman's Memorandum

TORONTO and CAMBRIDGE, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseas...
Previous 10 Next 10